AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04180358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Native STAND
Description: Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
Study NCT04180358 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular Health/Physical Education Curriculum
Description: General health and physical education curriculum provided by New Mexico's Public Education Department.
Study NCT03246893 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min
Study NCT03246893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen nasal cannula
Description: High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%
Study NCT02592356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies
Study NCT02592356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Correlative studies
Study NCT02592356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Correlative studies
Study NCT02592356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02592356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02592356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study NCT02592356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study NCT00659997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single oral dose of 400mg
Study NCT00659997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole
Description: Single oral dose of 2.5mg/kg
Study NCT00106197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/sqm iv over 60 minutes day 1
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-leucovorin
Description: 200 mg/sqm iv over 2 hours
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin
Description: 200 mg/sqm iv over 2 hours
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
Study NCT03748355 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Pharmacogentic Analysis
Description: Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
Study NCT03184259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Robotic ankle system
Description: Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
Study NCT03184259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic ankle system
Description: Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
Study NCT03184259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Robotic knee system
Description: Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
Study NCT03184259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic knee system
Description: Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
Study NCT03795831 — intervention group
Intervention type: DEVICE
Intervention: ClearSight feasibility testing
Description: A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
Study NCT03968770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
Study NCT03968770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo of Probiotic once daily taken by 6 weeks.
Study NCT03968770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual medical care
Description: NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
Study NCT03968770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual medical care
Description: NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
Study NCT04546061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Uplift
Description: Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
Study NCT02606448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Local infiltration of liposomal bupivacaine
Study NCT02606448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: Pre-operative femoral nerve block
Study NCT03231722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
Study NCT04306705 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Administered as an intravenous infusion.
Study NCT04306705 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
Study NCT03059719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide injection(Byetta)
Study NCT03059719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection
Study NCT01844622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Domperidone
Description: Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
Study NCT01464242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimonate
Description: Glucantime® 20mg/kg/day IM daily for 20 days
Study NCT01464242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meglumine antimonate
Description: Glucantime® 20mg/kg/day IM daily for 20 days
Study NCT01464242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400mg orally 3 times a day for 20 days
Study NCT01464242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg orally 3 times a day for 20 days
Study NCT01401465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide
Description: 74 mcg ciclesonide nasal aerosol once daily
Study NCT01401465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone
Description: 200 mcg mometasone aqueous nasal spray once daily
Study NCT03079349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Education
Description: All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
Study NCT03079349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Education
Description: All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
Study NCT03079349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Intervention
Description: All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
Study NCT03079349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Intervention
Description: All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
Study NCT01836211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast strategy
Description: High sensitivity troponin T followed by computed coronary tomography angiography
Study NCT01836211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care strategy
Description: Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
Study NCT02000453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 400mg
Description: White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
Study NCT01846117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: secoisolariciresinol diglucoside, vitamin D
Description: SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
Study NCT01846117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: secoisolariciresinol diglucoside, vitamin D
Description: SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
Study NCT02522403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
Study NCT02522403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Lever Laser acupuncture
Description: The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
Study NCT04019184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Alanyl/L-Glutamine
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
Study NCT04019184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
Study NCT02206620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study NCT02206620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Study NCT01720199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diario della Salute (DDS)
Description: DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers.
Study NCT00608192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Testing, Education, & Counseling (TEC)
Description: Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
Study NCT00608192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hepatitis Care Coordination (HCC)
Description: HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
Study NCT00916136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Traction
Description: Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
Study NCT01698437 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive intervention with focused ultrasound (ExAblate 4000)
Description: Non-invasive brain intervention using MR-guided focused ultrasound
Study NCT03516084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306(nirapairb)
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Study NCT03516084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: tablet
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: tablet
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole/trimethoprim
Description: tablet
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: tablet
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: tablet
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: tablet
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fusidic Acid
Description: tablet or ointment
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: tablet
Study NCT02121093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration
Study NCT01042314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Tablets, Oral, 5 mg, Once Daily, Days 1-28
Study NCT01042314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, Once Daily, Days 15-28
Study NCT04304560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: inhibitor of sodium-glucose cotransporter 2
Study NCT04304560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Similar Placebo oral tablet
Study NCT01697111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(BAY86-5300)
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Study NCT01697111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
Study NCT01697111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: Dienogest 1mg twice a day (bid)
Study NCT03239457 — intervention group
Intervention type: BIOLOGICAL
Intervention: Heberprot P
Description: 75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
Study NCT01141530 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
Study NCT02781441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question prompt list (QPL)
Study NCT02781441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education brochure of Groupe Français des Myélodysplasies
Study NCT02781441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education brochure of Groupe Français des Myélodysplasies
Study NCT01621178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT01621178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered SC
Study NCT01621178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered SC
Study NCT01621178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Administered SC
Study NCT04203472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Budesonid or budesonide/fomoterol administered by DPI
Description: Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
Study NCT04203472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Budesonid or budesonide/fomoterol administered by MDI
Description: Budiair 200 mcg or Atimos 12 mcg
Study NCT00831389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop
Description: Insulin pump controlled by closed loop unit and algorithm
Study NCT03319641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT scan
Description: perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
Study NCT02070653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study NCT02070653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01115907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom SOLO Stentless Heart Valve
Description: Freedom SOLO Stentless Heart Valve